The Food and Drug Administration (FDA) will convene a panel next week to re-evaluate the effectiveness of oral phenylephrine, a common ingredient found in numerous over-the-counter decongestants. The panel is slated meet Monday and Tuesday, just days after the FDA released a report claiming that phenylephrine likely doesn't work.
The panel will examine the potential benefits and drawbacks of phenylephrine and question medical advisers. The drug, which was first approved by the FDA in the 1970s, can be found in many varieties of anti-cold medications, including versions of Nyquil, Sudafed, Benadryl, Vicks and Mucinex.
These medications are currently classified as being "generally recognized as safe and effective," according to an FDA fact sheet. However, the FDA's recent report, released last Thursday, claimed that phenylephrine is unlikely to work in any dosages, putting that classification at high risk of being revoked.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"Because this would represent a major change in the agency's position, we believe that presenting this information in an open public forum, along with a full discussion and vote" from committee members, "will be extremely helpful," the FDA's report said.
If phenylephrine does end up being reclassified, major drug companies like Kenvue, Procter & Gamble, Reckitt Benckiser and others would likely have to reformulate many of their flagship decongestants or pull them from store shelves, Bloomberg reported.
The effectiveness of phenylephrine has long been debated. A 2015 clinical trial of 500 adults with seasonal allergies found that phenylephrine was "not significantly better than placebo at relieving nasal congestion in adults." Dr. Wynne Armand, a primary care doctor at Massachusetts General Hospital, told NBC News she advises patients with cold symptoms "to avoid buying oral meds that have phenylephrine," and won't prescribe it.
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.
-
Ben Fountain's 6 favorite books about HaitiFeature The award-winning author recommends works by Marie Vieux-Chauvet, Katherine Dunham and more
-
6 picturesque homes in apartments abroad
Feature Featuring a wall of windows in Costa Rica and a luxury department store-turned-home in New Zealand
-
Why 2023 has been the year of strikes and labor movements
The Explainer From Hollywood to auto factories, workers are taking to the picket lines
-
Popular weight loss drugs linked to higher risk of serious gastrointestinal problems
Speed Reads Researchers found that semaglutide, the active ingredient in Wegovy and Ozempic, had a higher risk for side effects like stomach paralysis.
-
What is a 'feminist approach' to cancer care?
The Explainer 800,000 women die from 'preventable' cancers each year due to 'patriarchy', landmark study finds
-
Animals and plants that have been used to fight disease
The Explainer The world's flora and fauna have long been medically important
-
Heat harms the brain more than we think
Warmer temperatures could be affecting us mentally
-
A flesh-eating bacteria is growing in numbers due to climate change
Speed Read
-
CDC recommends new RSV vaccine for infants under 8 months
Speed Read
-
Will Medicare drug price controls save lives?
Talking Point Medicare starts negotiating lower drug prices over Big Pharma protests
-
U.S. health agency advises easing federal marijuana restrictions
Speed Read
